Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer

Participants with confirmed or suspected lung cancer or malignant mesothelioma who are candidates for standard-of-care surgical tumor resection will be eligible for study participation and will undergo the following study procedures: * \*\*Microdevice implantation:\*\* Placement of 1-4 investigational drug-releasing microdevices into an accessible tumor approximately 72 ± 24 hours prior to scheduled standard-of-care surgery. Microdevices may be implanted using image-guided percutaneous techniques or other clinically appropriate approaches, depending on tumor location and accessibility. The number of microdevices implanted will be determined on a case-by-case basis based on tumor characteristics, anatomical location, procedural feasibility, and participant-specific considerations. * \*\*Microdevice retrieval and tissue collection:\*\* At the time of scheduled standard-of-care surgery, the implanted microdevices will be surgically retrieved along with surrounding tumor tissue and analyzed.